Preclinical Imaging Market Size Analysis, Growth Trends & Forecast to 2034

Preclinical Imaging Market Overview 

The global preclinical imaging market was valued at USD 2.9 billion in 2026 and is projected to reach USD 4.2 billion by 2034, expanding at a CAGR of 5.1% during the forecast period.  The preclinical imaging industry involves the technologies that are utilized for studying biological processes, disease progression, and treatment responses in small animals. Technologies like optical imaging, micro-MRI, micro-CT, micro-PET/SPECT, ultrasound, and photoacoustic imaging have become important tools in drug development, tumor research, investigation of brain functioning, heart disease diagnosis, regenerative medicine, and clinical studies.

The growth of the market is driven by the increasing number of R&D operations performed in biotechnology and pharmaceutical industries as well as by the advancement of imaging techniques. The cooperation of research institutes with CROs is also boosting the need for the implementation of preclinical technologies to increase the efficiency of research and shorten the time of the research process.

Preclinical Imaging Market Drivers and Opportunities

Rising Investment in Drug Discovery and Preclinical Research is Driving Market Growth

The rise in investments in the fields of preclinical research and drug discovery from groups in the fields of pharmaceuticals, biotech companies, and universities has resulted in a significant increase in the demand for preclinical imaging systems. With the advancing focus on rapid development of more therapeutics such as small molecules that perform multiple functions and new types of biological drugs intended for tough disease targets, modern imaging techniques have turned out to be vital in terms of drug efficacy and safety evaluation as well as drug distribution and workings in animals. The process of preclinical imaging allows for consistent and non-invasive tracking of the mutation process and how effective each of the drugs was. Taking this development into consideration, in April 2026, ELRIG announced that Drug Discovery USA 2026 will be held at Pfizer, which is located in Cambridge, Massachusetts.

Growing Demand for Multimodal and High-Resolution Imaging Technologies Fueling Market Expansion

The rising intricacy of drug development, cancerology, neurobiology, and heart and vascular disease calls for multimodal high-definition preclinical imaging technologies. Researchers increasingly need different data about an object derived from one study; thus, integrated imaging systems comprising micro-CT, micro-PET/SPECT, MRI, optical imaging, and photoacoustic imaging began to emerge rapidly. Such multimodal systems produce complementary datasets, which enhance the accuracy of disease characterizations, biomarker discoveries, and therapeutic efficiency evaluations and reduce the demand for numerous separate experiments. Meanwhile, innovations in detection technologies, image reconstruction algorithms, and AI-based image analysis markedly improve imaging accuracy, sensitivity, quantitative precision, and the effectiveness of work.

Expansion of Precision Medicine and Translational Research Presents Significant Opportunities

The rapid growth of precision medicine and translational research is creating significant growth prospects for the preclinical imaging market. There is an increased focus on developing targeted therapies, gene and cell therapies, immunotherapy, and personalized medicine options, which rely on advanced imaging technologies capable of noninvasively monitoring key aspects of the disease process. Preclinical imaging is a crucial instrument for connecting laboratory discoveries to clinical applications and producing reliable in vivo data that ensures accurate target validation and supports regulatory submissions. Moreover, rising collaboration with pharmaceutical and biotechnology companies, universities, and research organizations, as well as improved support for translational research, is accelerating the adoption of multimodal imaging systems.

Preclinical Imaging Market Scope

Preclinical Imaging Market Report Segmentation Analysis

The global preclinical imaging market industry analysis is segmented by modality, application, end user, and region. 

Optical Imaging Systems Segment Is Expected to Dominate the Preclinical Imaging Market During the Forecast Period

Due to their non-invasive nature, high sensitivity, real-time imaging capabilities, and cost-efficiency, it is expected that optical imaging systems' market shares will be the highest among the preclinical imaging market during the forecast period. Optical devices like bioluminescence imaging and fluorescence imaging are widely used in oncology, immunology, infectious diseases, and stem cell research to observe biological processes. Being able to measure disease development, response to therapy, and gene activities on a fast basis, this technology has become important in early drug discovery and other related fields. The trend towards multimodal imaging contributes significantly to optical systems since it allows the merging of them with MRI, microtomography, and PET/SPECT technologies. Thus, Bruker at PIC 2026 introduced the new initiative “Excellence in Every Modality," which presupposes one-stop approaches in the imaging of the particular test subject applying MRI and other technologies so that the obtained results are more qualitative and numerous.

Oncology Segment Is Expected to Lead the Preclinical Imaging Market by Application

Given the growing globalization of cancer drug discovery and the development of pipelines on targeted therapies, immunotherapy drugs, radiopharmaceuticals, and cell & gene therapy, it is anticipated that the oncology segment will account for the largest share of preclinical imaging in terms of application. With preclinical imaging enabling longitudinal and non-invasive tracking of tumor growth, metastasis, and treatment response in animal models, drug efficacy, biodistribution, and biomarker expression can be accurately assessed. The rise in the usage of multimodal imaging and PDX models, as well as AI-based analysis of preclinical data, is also of high support.

Pharmaceutical & Biotechnology Companies Segment Is Expected to Dominate the End User Segment

The preclinical imaging market is expected to be controlled by the segment of pharmaceutical & biotechnology companies, given the increase in investment in areas like drug discovery, biologics, precision medicine, and translational research. Preclinical imaging is used by these companies to check the safety, effectiveness, pharmacokinetics, and biodistribution of their drug candidates in animal models selected for these types of studies.

The following segments are part of an in-depth analysis of the global preclinical imaging market:

Preclinical Imaging Market Share Analysis by Region

North America is projected to hold the largest share of the global preclinical imaging market over the forecast period  

North America will command the largest share of the global market for preclinical imaging due to heavy investments made in the R&D segment, a developed life science sector, and the presence of major preclinical imaging vendors in this region. Moreover, the availability of significant funds for translational research and the quick adoption of advanced imaging modalities are additional advantages for this region. As such innovations continue, FUJIFILM VisualSonics Inc. introduced the Vevo F2 LAZR-X20 Photoacoustic Imaging Platform in June 2025, which uses intelligent high-power lasers to offer detailed characterization and high anatomical accuracy.

Preclinical Imaging Market Competition Landscape Analysis

The preclinical imaging market consists of companies involved in the development of modern imaging systems, software, imaging reagents, and affiliated services for pharmaceutical and biotechnology companies as well as research and academic facilities. By utilizing multimodal high-resolution imaging technologies and applying artificial intelligence in their products, companies are able to boost their competitive capabilities. Incorporating innovation in the field of optical imaging and expanding the number of strategic alliances, product launches, and distribution networks also augment the preclinical imaging market. 

Global Preclinical Imaging Market Recent Developments News:

●        In April 2026 - Bruker At PIC 2026, Bruker showcased its "Excellence in Every Modality" initiative, demonstrating an integrated workflow combining MRI, SPECT/CT, and Optical Imaging with PMOD software for unified quantitative analysis and enhanced multimodal preclinical imaging research.

●        In April 2026 - Bruker continued to expand its multimodal preclinical imaging ecosystem by promoting seamless integration of MRI, PET/SPECT, CT, optical imaging, and PMOD quantitative analysis workflows for longitudinal animal studies at international scientific meetings.

●        In June 2025 - FUJIFILM VisualSonics launched the Vevo F2 LAZR-X20 Photoacoustic Imaging Platform, an advanced multimodal ultrasound and photoacoustic imaging system featuring intelligent laser technology for high-resolution tissue characterization and improved anatomical accuracy in preclinical animal models.

●        In April 2025 - Revvity introduced the VivoJect Image-Guided Injection System at AACR 2025, enabling precise image-guided injections in preclinical animal models to improve reproducibility and efficiency in oncology and translational research workflows.

The global preclinical imaging market is dominated by a few large companies, such as

●        Advanced Molecular Vision, Inc.

●        Aspect Imaging Ltd

●        AXT Pty Ltd

●        Bruker Corporation

●        Cubresa Inc.

●        FUJIFILM Holdings Corporation

●        IVIM Technology Corp.

●        Mediso Ltd

●        MILabs B.V.

●        Miltenyi Biotec B.V. & Co. KG

●        MR Solutions Ltd

●        PerkinElmer Inc.

●        Photon etc.

●        Rigaku Corporation

●        Scanco Medical AG

●        Siemens Healthineers AG

●        Thermo Fisher Scientific Inc.

●        Trifoil Imaging

●        United Imaging Healthcare Co. Ltd

●        VisualSonics Inc. (FUJIFILM Sonosite)

●        Other Prominent Players